Aranesp Oncology Costs: “Exorbitant” (J&J); “Very Competitive” (Amgen)

An Aranesp (darbepoetin) dosing regimen in oncology using a "priming" dose followed by a reduced maintenance dose creates a cost of treatment comparable to Johnson & Johnson's Procrit (epoetin alfa), Amgen maintains